Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

por Berenbaum, Francis, Blanco, Francisco J, Guermazi, Ali, Miki, Kenji, Yamabe, Takaharu, Viktrup, Lars, Junor, Rod, Carey, William, Brown, Mark T, West, Christine R, Verburg, Kenneth M
Publicado 2020

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

por Berenbaum, Francis, Langford, Richard, Perrot, Serge, Miki, Kenji, Blanco, Francisco J, Yamabe, Takaharu, Isogawa, Naoki, Junor, Rod, Carey, William, Viktrup, Lars, West, Christine R, Brown, Mark T, Verburg, Kenneth M
Publicado 2021